Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Tatiana Perova, Onsay Lau, Cuc Davis, Yue Guo, Xin Miao, Tara Stephenson, Caroline Hodin, Clarissa Uhlar, Danielle Trancucci, Katherine Chastain, Nizar J Bahlis, Niels W.C.J. Van De Donk, Raluca Verona

Blood (2023) 142 (Supplement 1): 455.

https://doi.org/10.1182/blood-2023-173550

Published: 2023

Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona

Blood (2023) 142 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2023-187755

Published: 2023

Journal Articles

Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Jia Zhou, Deeksha Vishwamitra, Yue Guo, Raluca Verona, Alfredo Perales Puchalt, Tara Stephenson, Caroline Hodin, Arnob Banerjee, Katherine Chastain, Nahor Haddish-Berhane, Weirong Wang

Blood (2023) 142 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2023-180208

Published: 2023

Journal Articles

Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells

Dennis J Wu, Amy S Chen, Nikki Deangelis, Diana Cortes, Jose Morachis, Benjamin Titz, Sylvaine Cases, Raluca Verona, Chorom Pak

Blood (2023) 142 (Supplement 1): 3659.

https://doi.org/10.1182/blood-2023-190245

Published: 2023

Journal Articles

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis

Blood (2022) 140 (Supplement 1): 7253–7254.

https://doi.org/10.1182/blood-2022-162856

Published: 2022

Journal Articles

Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples

Katherine Li, David Barnidge, Maria Krevvata, Mark C. Perkins, Raluca Verona, Enrique Zudaire

Blood (2022) 140 (Supplement 1): 12446–12447.

https://doi.org/10.1182/blood-2022-160249

Published: 2022

Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4382–4383.

https://doi.org/10.1182/blood-2022-162859

Published: 2022

Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Blood (2022) 140 (Supplement 1): 241–243.

https://doi.org/10.1182/blood-2022-162709

Published: 2022

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Christie P.M. Verkleij, MD, Marloes Broekmans, Amy Wong, Sonja Zweegman, MDPhD, Raluca Verona, PhD, Homer Adams, III, PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141187

Published: 2020

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Enrique Zudaire, PhD, Deepu Madduri, MD, Saad Z. Usmani, MD FACP, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD, Dong Geng, Syed Rizvi, MD, Tonia Nesheiwat, Jordan M Schecter, MD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Alicia J. Allred, PhD, Indrajeet Singh, PhD, Raluca Verona, PhD, Ian McCaffery, PhD, Sundar Jagannath

Blood (2019) 134 (Supplement_1): 928.

https://doi.org/10.1182/blood-2019-127309

Published: 2019

NARROW

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only